| Abstrakt: |
The aim of this study was to develop a long-acting injectable formulation of risperidone using polylactic acid (PLA) or poly (lactic-co-glycolic acid) (PLGA), a biodegradable and biocompatible polymer. Risperidone microspheres (RMs) were prepared by creating an O/W emulsion using dichloromethane (DCM) as a solvent and then employing the solvent evaporation method. The RMs were prepared with four different risperidone-to-PLGA ratios (1:1, 1:1.3, 1:2, and 1:3 (w/w)), and each ratio was subjected to the same manufacturing process. The physicochemical properties of the prepared RMs, such as their shape, particle size, drug loading ratio, encapsulation efficiency, and in vitro degradation profile, were evaluated. The particle size of the RMs ranged from 30 to 100 μm, with larger PLGA ratios resulting in larger RM sizes. The drug loading ratio was inversely proportional to the increase in the PLGA ratio in the RMs, and all the formulations showed improved release profiles compared to the reference drug, Risperdal Consta®. The release data modeling results showed that the RM-3 formulation with a 1:1 (w/w) ratio of risperidone and PLGA exhibited a release pattern close to zero-order kinetics. The manufactured RMs were confirmed to have the potential to be used as a long-acting risperidone injection with sustained and stable release as well as an extended dosing interval. [ABSTRACT FROM AUTHOR] |
